All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional.

The GvHD Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Introducing

Now you can personalise
your GvHD Hub experience!

Bookmark content to read later

Select your specific areas of interest

View content recommended for you

Find out more
  TRANSLATE

The GvHD Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the GvHD Hub cannot guarantee the accuracy of translated content. The GvHD Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact
LOADING
You're logged in! Click here any time to manage your account or log out.
LOADING
You're logged in! Click here any time to manage your account or log out.
2023-05-03T15:13:54.000Z

How to sequence agents for steroid-refractory chronic GvHD

May 3, 2023
Share:
Learning objective: After reading this article, learners will be able to cite a new clinical development in steroid-refractory GvHD.

During the GvHD Hub Steering Committee meeting, key opinion leaders met to discuss how to sequence agents for steroid-refractory chronic GvHD. This recorded discussion was chaired by Mohamad Mohty, and featured Hildegard Greinix, Yi-Bin Chen, Attilio Olivieri, Mutlu Arat, Arnon Nagler, Florent Malard, Bipin Savani, and Ali Bazarbachi.

How to sequence agents for steroid-refractory chronic GvHD

The members considered a case study presented by Mohamad Mohty and discussed their management strategies for this patient, weighing up the efficacy of alternative treatments. This case study is outlined in Figure 1.

Figure 1. Case study outline 

aGvHD, acute GvHD; allo-HSCT, allogenic hematopoietic stem cell transplantation; AML, acute myeloid leukemia; cGvHD, chronic GvHD; CR1, complete response.

Treatment options

There are multiple appropriate treatments for this case, one being ruxolitinib due to its benefits in mucosal cGvHD as well its use to accelerate the tapering of previous steroid treatment. Extracorporeal photopheresis (ECP) may also be considered, with recent clinical data suggesting ECP is particularly effective in skin and oral presentations of GvHD. A combination therapy of ruxolitinib and ECP has also been shown to be effective in this group and can serve to faster taper steroids. The most appropriate drug or combination (Figure 2) can be determined by the risk of relapse and any other individual considerations for the patient.

Figure 2. Treatment options for cutaneous mucosal presentations of steroid-refractory chronic GvHD 


Case scenario variations

Certain variations to the case presentation may influence the management options. For example, ibrutinib is an alternative that may be considered for patients, particularly those with B-cell malignancies; however, other than in this specific patient group, ibrutinib is a lower priority option due to its reduced efficacy and higher toxicity in comparison with ruxolitinib.

In the case of cytopenia and cytomegalovirus reactivation, ECP would be more appropriate. Furthermore, the addition of moderate lung involvement to this scenario would indicate alternative treatments such as belumosudil, which has a slightly higher overall response rate in lung manifestations of cGvHD compared with ruxolitinib.1

Conclusion

Multiple options are available for the treatment of patients with steroid-refractory cGvHD. The most appropriate management strategies depend on the individual presentation of the patient, in particular the organ manifestations present and may include a singular therapy or a combination treatment regimen.

  1. Cutler C, Lee SJ, Arai S, et al. Belumosudil for chronic graft-versus-host disease after 2 or more prior lines of therapy: the ROCKstar study. 2021;138(22):2278–2289. DOI: 10.1182/blood.2021012021

Newsletter

Subscribe to get the best content related to GvHD delivered to your inbox